Key facts
- This page summarizes Gena L. Ashe's Form 4 filing for Anterix Inc. (ATEX).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2026, 19:10.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options Exercise
Tax liability
Tax liability
Sale
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Additional SEC filing notes
Footnote F1
The Reporting Person exercised a stock option to purchase 11,000 shares of the Issuer's Common Stock for $34.96 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding an aggregate of 4,661 shares of the Issuer's Common Stock subject to the stock option to pay the exercise price and to satisfy its income tax withholding and remittance obligations in connection with the exercise of the stock option. The withholding of shares referenced here does not involve an open market sale of stock.
Footnote F2
The Reporting Person exercised a stock option to purchase 18,368 shares of the Issuer's Common Stock for $49.39 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding an aggregate of 10,996 shares of the Issuer's Common Stock subject to the stock option to pay the exercise price and to satisfy its income tax withholding and remittance obligations in connection with the exercise of the stock option. The withholding of shares referenced here does not involve an open market sale of stock.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
Footnote F4
The option shares subject to this option shall vest and become exercisable in three equal annual installments, with 1/3 of the option shares vesting and becoming exercisable on May 20, 2026, and with the remaining option shares vesting and becoming exercisable in two equal annual installments thereafter.
Footnote F5
The option shares are fully vested.